At #EAU25, Dr. Lotte Zuur from the The Netherlands Cancer Institute presented the first results of the PROQURE-I study, a phase I trial evaluating the addition of [¹⁷⁷Lu]Lu-PSMA-617 to standard EBRT and long-term ADT in patients with newly diagnosed N1M0 prostate cancer.
This prospective, dose-escalation trial demonstrated that the integration of 9 GBq [¹⁷⁷Lu]Lu-PSMA-617 was well tolerated, with no grade ≥3 toxicity reported. The radioligand therapy delivered significant absorbed doses to primary tumors and lymph node metastases, while maintaining low exposure to critical organs such as the kidneys, rectum, and bones. All grade 1–2 toxicities observed were consistent with standard EBRT.
These findings suggest that incorporating PSMA-targeted therapy may intensify local and microscopic disease control without compromising safety in the curative setting. The study is now progressing to assess two cycles of 7.4 GBq [¹⁷⁷Lu]Lu-PSMA-617, with updated results expected in March 2025.
We thank Dr. Zuur and all collaborators for sharing this important advancement in the multimodal treatment of N1 prostate cancer.
For more information, please visit: https://lnkd.in/dkr7R2kf
